Ludwig Enterprises, Inc.

Ludwig Enterprises pivoted to genomics in late 2021, focusing on non-invasive cheek swab mRNA tests to detect inflammation-driven cancers via proprietary 48-gene panels and ML algorithms. The lead Revealia Breast test showed promising preliminary metrics (92% sensitivity in 249 samples) but remains pre-revenue with planned Q1 2026 launch dependent on this $13.6M raise. Targeting Nasdaq uplisting (RVLA) via 1:200 reverse split, the firm addresses a $4.5B US breast diagnostics TAM amid gaps in early detection—mammography misses interval cancers, no routine ovarian screening exists. Pipeline expansion to lung/ovarian/pancreatic leverages same platform, positioning against DNA-focused rivals like Natera (Signatera) and Guardant (Shield) via real-time mRNA expression vs. static genetics.

Financially precarious: FY2025 loss widened to $2.24M on $1.77M opex (up 37% YoY from R&D/marketing ramp), zero revenue, $4.4M working cap deficit, $4.6M liabilities (mostly convertible notes at 85% VWAP discount post-uplisting). Auditors flag going concern; burn rate implies <3 months runway without funding. Post-raise pro forma cash jumps to $12.8M, turning stockholders' deficit positive at $11.2M, but dilution hits new investors at $7.24/share vs. $1.74 post-money book value.

Proceeds prioritize $6.4M clinical studies (insufficient alone per filing), $4.3M sales/marketing for B2B2C model via labs/physicians, $1.1M debt paydown. Uplisting critical—failure kills offering, triggers note defaults. LDT status offers regulatory runway but FDA scrutiny looms; IP comprises 2 PCT families (pending). Officers/directors lockup 6 months, 5% holders 3 months; insiders hold ~53% post-offering.

Risks center on execution: no sales history, validation unpeer-reviewed/FDA-free, supply chain for NGS reagents vulnerable, heavy consultant reliance (3 execs). Comp moat via buccal mRNA novel but unproven vs. blood/stool incumbents with reimbursement. Success hinges on validation data, Nasdaq approval, and B2B2C traction before cash burnout.